Anti-CD20 monoclonal antibodies: historical and future perspectives
Anti-CD20 monoclonal antibodies: historical and future perspectives
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. In this review, we discuss the history of anti-CD20 monoclonal antibodies, detail their likely mechanisms of action, and explore ways in which they might be enhanced and further exploited in the future. In particular, as we develop our understanding of the relative contribution of the diverse effector mechanisms for different antibodies, so we hope to clarify which reagent will be the most effective in each clinical situation.
cd20, monoclonal antibodies, lymphoma, immunotherapy
135-143
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
1 January 2010
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W., Glennie, Martin J. and Cragg, Mark S.
(2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives.
Haematologica, 95 (1), .
(doi:10.3324/haematol.2008.001628).
(PMID:19773256)
Abstract
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. In this review, we discuss the history of anti-CD20 monoclonal antibodies, detail their likely mechanisms of action, and explore ways in which they might be enhanced and further exploited in the future. In particular, as we develop our understanding of the relative contribution of the diverse effector mechanisms for different antibodies, so we hope to clarify which reagent will be the most effective in each clinical situation.
This record has no associated files available for download.
More information
e-pub ahead of print date: 22 September 2009
Published date: 1 January 2010
Keywords:
cd20, monoclonal antibodies, lymphoma, immunotherapy
Identifiers
Local EPrints ID: 153653
URI: http://eprints.soton.ac.uk/id/eprint/153653
ISSN: 0390-6078
PURE UUID: cd711606-37d6-4343-9a16-2026972a6a72
Catalogue record
Date deposited: 20 May 2010 14:51
Last modified: 14 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
Ruth R. French
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
